Silence Therapeutics
SLN · Nasdaq · United Kingdom
Share price · SLN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SLN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 19 Oct 2026+125.6%
- 10 Aug 2026+29.1%
- 22 Jul 2026+9.0%
Nothing announced by SLN that day or the session before.
- 24 Jun 2026+26.0%
- 15 May 2026-14.4%
Nothing announced by SLN that day or the session before.
- 15 Apr 2026+19.0%
Nothing announced by SLN that day or the session before.
- 11 Mar 2026+11.3%
Nothing announced by SLN that day or the session before.
- 6 Mar 2026+13.3%
- 2 Mar 2026+9.9%
Nothing announced by SLN that day or the session before.
- 17 Feb 2026+12.6%
Nothing announced by SLN that day or the session before.
Share of unusual movement by asset
For each asset, the share of SLN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Zerlasiranevents and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 6% |
| Other company news (earnings, financing, releases naming no asset) | — | 60% |
| Sessions with no dated event | — | 34% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | LPA gene / apolipoprotein(a) mRNARNA / oligonucleotide | Atherosclerotic Cardiovascular Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (9)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $9.3M | $248M+ $0 short-term inv. | $12M-$13M operating cash flow | report ↗ |
View 8 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $9.2M | $72M+ $0 short-term inv. | $12M$1.5M operating cash flow | report ↗ |
| 2026-Q1 | $0.4M | $9.1M | $5.7M+ $64M short-term inv. | $15M-$16M operating cash flow | report ↗ |
| 2025-Q3 | $0.2M | $21M | $82M+ $20M short-term inv. | $21M-$11M operating cash flow | report ↗ |
| 2025-Q2 | $0.2M | $18M | $42M+ $72M short-term inv. | $27M-$22M operating cash flow | report ↗ |
| 2025-Q1 | $0.1M | $21M | $65M+ $72M short-term inv. | $29M-$12M operating cash flow | report ↗ |
| 2024-Q3 | $1.5M | $20M | — | $36M-$26M operating cash flow | report ↗ |
| 2024-Q2 | $0.8M | $14M | — | $20M-$5.4M operating cash flow | report ↗ |
| 2024-Q1 | $16M | $12M | — | $2.3M-$9.1M operating cash flow | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.6M | $68M | $11M+ $74M short-term inv. | $22M-$62M operating cash flow | report ↗ |
Silence Therapeutics reported full-year 2025 revenue of $0.56M, down 98.7% YoY, with R&D spend of $67.75M, down 0.2% YoY. Cash and cash equivalents were $11.28M, and total cash, cash equivalents, and short-term investments were $85.1M at year-end. The company reported a net loss of $88.61M, or $0.63 per basic and diluted share.
Management reiterated that topline results for the Phase 2 SANRECO trial of divesiran in polycythemia vera remain on track for the third quarter of 2026, while zerlasiran is positioned as a Phase 3-ready program for potential partnering. AstraZeneca notified Silence that it will not advance SLN312 beyond Phase 1, returning global rights to Silence, and preclinical data for SLN365 and SLN098 are expected in the second quarter of 2026. Corporate updates included an interim principal executive officer appointment and board changes.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-10 | Griffiths Richard Ian · 10% owner | Open-market sale (derivative) | 2,792,826 | — | — | Form 4 |
| 2026-08-10 | Griffiths Richard Ian · 10% owner | Open-market sale (derivative) | 100,000 | — | — | Form 4 |
| 2026-08-10 | Griffiths Richard Ian · 10% owner | Open-market sale (derivative) | 50,000 | — | — | Form 4 |
| 2026-08-10 | Griffiths Richard Ian · 10% owner | Open-market sale (derivative) | 3,500 | — | — | Form 4 |
| 2026-08-10 | Griffiths Richard Ian · 10% owner | Open-market sale (derivative) | 800,000 | — | — | Form 4 |
| 2026-08-10 | Griffiths Richard Ian · 10% owner | Open-market sale (derivative) | 382,000 | — | — | Form 4 |
| 2026-08-10 | Griffiths Richard Ian · 10% owner | Open-market sale (derivative) | 470,820 | — | — | Form 4 |
| 2026-08-10 | Griffiths Richard Ian · 10% owner | Open-market sale (derivative) | 605,174 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 56 reporting institutions held 19.9M shares ($100.5M, 14.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | TCG Crossover Management, LLC | 3,033,560 | $16.0M |
| 2 | Siren, L.L.C. | 2,911,438 | $15.3M |
| 3 | Redmile Group, LLC | 2,164,777 | $11.4M |
| 4 | Nantahala Capital Management, LLC | 2,146,731 | $11.3M |
| 5 | CITADEL ADVISORS LLC | 1,234,807 | $6.5M |
| 6 | MILLENNIUM MANAGEMENT LLC | 1,074,191 | $5.7M |
| 7 | GREAT POINT PARTNERS LLC | 1,020,489 | $5.4M |
| 8 | Nextech Invest, Ltd. | 952,400 | $5.0M |
| 9 | Tetragon Partners GP Ltd | 630,161 | $3.3M |
| 10 | 5AM Venture Management, LLC | 476,200 | $2.5M |
| 11 | Ikarian Capital, LLC | 865,784 | $1.7M |
| 12 | Jones Hill Capital LP | 301,604 | $1.6M |
| 13 | UBS Group AG | 246,937 | $1.3M |
| 14 | BOOTHBAY FUND MANAGEMENT, LLC | 209,088 | $1.1M |
| 15 | BlackRock, Inc. | 204,777 | $1.1M |